Evaluation of Lipid Nanoparticles as Vehicles for Optogenetic Delivery in Primary Cortical Neurons
Authors:
- José David CeldránJCJosé David Celdrán
- Lawrence HumphreysLHLawrence Humphreys
- Maria Jose VerdúMVMaria Jose Verdú
- Desirée GonzálezDGDesirée González
- Cristina Soto-SánchezCSCristina Soto-Sánchez
- Gema Martínez-NavarreteGMGema Martínez-Navarrete
- Lucía EnríquezLELucía Enríquez
- Iván MaldonadoIMIván Maldonado
- Idoia GallegoIGIdoia Gallego
- Mohamed MashalMohamed Mashal
- Noha AttiaNANoha Attia
- Gustavo PurasGPGustavo Puras
Open Access
- 19 December 2025
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (1) , 4
Abstract
Background: Gene therapy has experienced significant development since its origin decades ago, resulting in therapies for a wide range of diseases. In this context, optogenetics has emerged as a promising therapy for treating diseases in a precise spatiotemporal way using light. Transporting optogenetic genes to target cells is achieved using viral vectors, specifically AAV vectors. These vectors present limited cargo capacity, and a large percentage of the population carries AAV neutralizing antibodies. In this regard, lipid nanoparticles can overcome some of the previously mentioned problems of AAV vectors, making them prime candidates for optogenetic delivery. Methods: In this study, we evaluated their suitability for the delivery of the ChrimsonR plasmid in neurons in vitro. Results: In rat cortical neurons, in most of the concentrations tested, there was no reduction in several neuron morphological parameters that we measured when compared to another non-viral nanoparticle called lipofectamine. Transfection efficiency was significantly higher compared to lipofectamine in almost all treatments. Further in vitro analysis showed that electrophysiological parameters were altered, with reduced signal amplitudes; however, cell viability assays showed no decline in cell viability. Conclusions: These results demonstrate that lipid nanoparticles represent a promising non-viral platform for optogenetic delivery, though formulation optimization is required to achieve full functional efficacy.Keywords
Funding Information
- Ministerio de Ciencia e Innovación (RTI2018-098969-B-I00)
- Ministerio de Ciencia e Innovación (PRE2019-087693)
- Ministerio de Ciencia e Innovación (DTS19/00175)
- Ministerio de Ciencia e Innovación (PDC2022-133952-100)
- Ministerio de Ciencia e Innovación (PID2019-106199RB-C21)
- Ministerio de Ciencia e Innovación (PRE 202210042)
- European Union’s Horizon 2020 Research and Innovation Programme (No. 899287)
This publication has 63 references indexed in Scilit:
- Breaking the final barrier: Evolution of cationic and ionizable lipid structure in lipid nanoparticles to escape the endosomeAdvanced Drug Delivery Reviews, 2024
- ERRα regulates synaptic transmission through reactive oxygen species in hippocampal neuronsHeliyon, 2023
- Delandistrogene Moxeparvovec: First ApprovalDrugs, 2023
- Structural and functional changes of deep layer pyramidal neurons surrounding microelectrode arrays implanted in rat motor cortexActa Biomaterialia, 2023
- Biodegradable Cationic and Ionizable Cationic Lipids: A Roadmap for Safer Pharmaceutical ExcipientsSmall, 2023
- Structure and Function of Cationic and Ionizable Lipids for Nucleic Acid DeliveryPharmaceutical Research, 2023
- Biodistribution and Non-linear Gene Expression of mRNA LNPs Affected by Delivery Route and Particle SizePharmaceutical Research, 2022
- Aerosolizable siRNA-encapsulated solid lipid nanoparticles prepared by thin-film freeze-drying for potential pulmonary deliveryInternational Journal of Pharmaceutics, 2021
- Lipid nanoparticles-encapsulated brain-derived neurotrophic factor mRNA delivered through the round window niche in the cochleae of guinea pigsExperimental Brain Research, 2020
- Redox‐Responsive Nanoparticle‐Mediated Systemic RNAi for Effective Cancer TherapySmall, 2018